Evidence map›Paper›PMID 16372188›Full record

ArticleDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2006

[Surgical considerations for gastrointestinal stroma tumor].

P Hohenberger, E Wardelmann

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).International journal of clinical and experimental pathology · 2014
    Article
  2. Article
  3. Gastrointestinal stromal tumors.International journal of colorectal disease · 2012
    Review
  4. Review
  5. [Tumors of the lower gastrointestinal tract : Indication and extent of lymph node dissection].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2010
    Article
  6. Review
  7. Article
  8. [Gastrointestinal stromal tumors (GIST). Surgical therapy].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2008
    Review
  9. Article
  10. Article
  11. [Lymphadenectomy with tumors of the lower gastrointestinal tract].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2007
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

P HohenbergerSektion Spezielle Chirurgische Onkologie und Thoraxchirurgie, Chirurgische Universitätsklinik, Fakultät Klinische Medizin Mannheim der Universität Heidelberg. hohenberger@sarkome.de
E Wardelmann
Heidelberg University · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal stroma tumors (GIST), an abdominal stroma entity, are characterized by a gain-in-function mutation in the c-kit proto-oncogen (CD117). Initial treatment should aim at complete removal of the primary tumor (R0 resection), which almost never develops lymphatic metastases. Distant metastatic spread mainly involves the peritoneal cavity and the liver. In patients with metastatic disease, treatment with the tyrosine kinase inhibitor imatinib mesylate is indicated and very effective. Systemic chemotherapy and external beam radiation must be considered ineffective. Patients requiring multivisceral resection for primary tumor removal quickly develop tumor recurrence and could benefit from preoperative treatment with imatinib. To assess the response to treatment, 18F-FDG positron emission tomography or gadolinium-enhanced magnetic resonance imaging have proven helpful, as the conventional criteria of tumor shrinkage according to WHO standards are rarely met. Primary tumors are classified into four risk categories according to size and mitotic activity. The possible advantages of adjuvant treatment are currently under investigation through international randomized trials. Patients who develop extensive remission of metastatic disease should be evaluated individually for resection of the tumor remnants. Even the resection of single progressive lesions (newly developed mutations) should be considered in carefully selected patients if the remaining tumor can be controlled by continued imatinib treatment.

Indexed as

Antigens, CD34ApoptosisBiomarkers, TumorDNA Mutational AnalysisGastrointestinal Stromal TumorsGastrointestinal TractGene Expression Regulation, NeoplasticGenes, rasHumansLymphatic MetastasisNeoplasm StagingPrognosisProto-Oncogene Proteins c-kitAntigens, CD34Biomarkers, TumorProto-Oncogene Proteins c-kit

Identifiers

PMID16372188
OpenAlexW2406969197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.